ID   HepG2/Adm
AC   CVCL_M187
SY   HepG2/ADM; Hep-G2/ADM; Hep G2/ADM
DR   BTO; BTO:0006029
DR   Wikidata; Q54882859
RX   PubMed=14980111;
RX   PubMed=15087025;
RX   PubMed=17075973;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from sampling site: Liver.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 20-05-21; Version: 14
RX   PubMed=14980111;
RA   Zhai B.-J., Wu F., Shao Z.-Y., Hu K., Zhao C.L., Wang Z.-B.;
RT   "Establishment of human hepatocellular carcinoma multidrug-resistance
RT   cell line (HepG2/Adm) and study apoptosis induced by low-frequency
RT   pulse ultrasound exposure.";
RL   Zhonghua Gan Zang Bing Za Zhi 12:95-98(2004).
RX   PubMed=15087025;
RA   Zhai B.-J., Wu F., Shao Z.-Y., Hu K., Wang Z.-B.;
RT   "Establishment of human multidrug-resistant hepatocellular carcinoma
RT   cell line (HepG2/Adm) and biological characteristics evaluation.";
RL   Ai Zheng 23:391-395(2004).
RX   PubMed=17075973; DOI=10.3748/wjg.v12.i41.6614;
RA   Zhai B.-J., Shao Z.-Y., Zhao C.-L., Hu K., Wu F.;
RT   "Development and characterization of multidrug resistant human
RT   hepatocarcinoma cell line in nude mice.";
RL   World J. Gastroenterol. 12:6614-6619(2006).